Evonik stock gains 3.71 percent as restructuring deepens

Published on 09/23/2026 at 15:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock closed at EUR 17.88 on September 22, 2026, up 3.71 percent from EUR 17.24. Sales reached EUR 14.1 billion in fiscal year 2025.

Fotorealistisches Luftbild eines Spezialchemiewerks mit Destillationstürmen bei Sonnenuntergang — Evonik Industries DE000EVNK013 zeigt ein fotorealistisches Luftbild eines großen Spezialchemiewerks bei Abenddämmerung, Illustration mit AI erstellt.

Evonik Industries AG (ISIN DE000EVNK013) closed at EUR 17.88 on Xetra on September 22, 2026, gaining 3.71 percent from the previous close of EUR 17.24. The move gives the stock a clear market catalyst while restructuring remains the central operating issue.

Restructuring sets the tone

According to ECHEMI on September 23, 2026, Evonik reported sales of EUR 14.1 billion and adjusted EBITDA of EUR 1.9 billion for fiscal year 2025. The same report said the company plans to cut 3,200 jobs globally, making cost reduction a measurable part of the investment case.

The figures provide a useful scale for the restructuring: adjusted EBITDA represented about 13.5 percent of fiscal-year sales, calculated from the reported EUR 1.9 billion and EUR 14.1 billion figures. That comparison places operating profitability at the center of the stock narrative rather than treating the workforce reduction as an isolated headline.

Stock reaction has a dated base

Evonik stock traded at EUR 17.88 at 4:20 p.m. on September 22, 2026, according to dated Xetra market data. The session high was EUR 17.95, while the prior close stood at EUR 17.24, producing the reported EUR 0.64 gain.

A separate September 23, 2026 market snapshot placed Evonik's market capitalization at EUR 8.03 billion and cited a September 22 closing level of EUR 17.98. The small difference between the quoted closing figures reflects separate market-data snapshots, so the Xetra close of EUR 17.88 remains the reference value used here.

Price keeps the risk visible

The restructuring figures also identify the main counter-factor: execution. A workforce reduction of 3,200 positions can lower costs, but the stock still depends on whether the EUR 1.9 billion adjusted EBITDA base improves relative to EUR 14.1 billion in fiscal-year sales.

For investors, the numerical gap between sales and earnings is the key checkpoint. The September 22, 2026 price reaction was positive, but the next durable move will require evidence that restructuring converts into higher profitability rather than only lower headcount.

Evonik stock closes at EUR 17.88

Evonik stock closed at EUR 17.88 on Xetra on September 22, 2026, up 3.71 percent from EUR 17.24. The dated market value and the fiscal-year 2025 operating figures provide the clearest reference points for assessing the restructuring story.